Trial Profile
A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Upadacitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms SELECT-BEYOND
- Sponsors AbbVie
- 15 Nov 2023 Results of an integrated analysis assessing gene expression and methylation identifies biomarkers associated with mode of action of Upadacitinib from three phase 3 clinical studies: SELECT-BEYOND, SELECT-COMPARE and SELECT-NEXT presented at the ACR Convergence 2023
- 12 Jun 2023 Results of post-hoc pooled analysis of 6 studies (NCT02706873, NCT02675426, NCT02629159, NCT02706951, NCT02706847 and NCT03086343) assessing potential risk of upadacitinib in a similar RA population, published in the Annals of the Rheumatic Diseases.
- 01 May 2023 Results of integrated safety analysis from NCT02706873; , NCT02675426;, NCT02629159; NCT02706951;NCT02706847; NCT03086343, published in the Clinical Rheumatology